Story perspectives

Neumora's Depression Drug Trial Fails; Shares Plunge 80%

1/3/2025

23 2

Summary

Neumora's Trial Failure

Neumora Therapeutics' navacaprant for depression failed its initial Phase 3 trial, missing key endpoints.
Following the announcement, shares dropped 80% to $2.05.
Both treatment and placebo groups exhibited similar reductions in depression scores.
The company will further investigate the results and provide updates at the J.P. Morgan Healthcare Conference in January.
Neumora retains a cash reserve of $342 million, ensuring operations through mid-2026.

Summary

Navacaprant's Efficacy Disappoints

Navacaprant demonstrated no significant efficacy in reducing depression scores compared to placebo, as indicated by p-values.
The drug was deemed safe, with no serious adverse events or heightened suicidal thoughts reported.
Headache and diarrhea were the most frequently reported side effects.
An impressive 83.3% of patients on navacaprant chose to participate in a follow-up study.

History

Historical Context

Neumora Therapeutics' navacaprant trial failure echoes past pharmaceutical setbacks, like the 2012 failure of Eli Lilly's antidepressant, which also saw significant stock drops. Such events highlight the high stakes in drug development, where initial promise can quickly turn to disappointment, affecting investor confidence and future research funding.

1 of 3

Neumora's Trial Failure

Neumora Therapeutics' navacaprant for depression failed its initial Phase 3 trial, missing key endpoints.
Following the announcement, shares dropped 80% to $2.05.
Both treatment and placebo groups exhibited similar reductions in depression scores.
The company will further investigate the results and provide updates at the J.P. Morgan Healthcare Conference in January.
Neumora retains a cash reserve of $342 million, ensuring operations through mid-2026.

1 / 3